HONOKIOL

Possibly Marketed Outside US

First approved in 2021

Details

Stereochemistry	ACHIRAL
Molecular Formula	C18H18O2
Molecular Weight	266.3343
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC1=CC=C(CC=C)C=C1C2=CC(CC=C)=C(O)C=C2

InChI

InChIKey=FVYXIJYOAGAUQK-UHFFFAOYSA-N

InChI=1S/C18H18O2/c1-3-5-13-7-9-18(20)16(11-13)14-8-10-17(19)15(12-14)6-4-2/h3-4,7-12,19-20H,1-2,5-6H2

HIDE SMILES / InChI

Molecular Formula	C18H18O2
Molecular Weight	266.3343
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27671820 | https://www.ncbi.nlm.nih.gov/pubmed/28817221 | http://adisinsight.springer.com/drugs/800042917

Honokiol is a biphenolic natural product isolated from the bark and leaves of Magnolia plant spp. Honokiol possesses anti-carcinogenic, anti-inflammatory, anti-oxidative, anti-angiogenic as well as the inhibitory effect on malignant transformation of papillomas to carcinomas in vitro and in vivo animal models without any appreciable toxicity. Honokiol affects multiple signaling pathways, molecular and cellular targets including nuclear factor-κB (NF-κB), STAT3, epidermal growth factor receptor (EGFR), cell survival signaling, cell cycle, cyclooxygenase and other inflammatory mediators, etc. Honokiol can permeate the blood-brain barrier and the blood-cerebrospinal fluid to increase its bioavailability in neurological tissues. Diverse studies have provided evidence on the neuroprotective effect of honokiol in the central nervous system, due to its potent antioxidant activity, and amelioration of the excitotoxicity mainly related to the blockade of glutamate receptors and reduction in neuroinflammation. Honokiol can attenuate neurotoxicity exerted by abnormally aggregated Abeta in Alzheimer's disease. Honokiol is being developed by Huons as HL tablet for the treatment of alcoholic and non-alcoholic fatty liver.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
NF-kappa B signaling pathway 79 Target ID: map04064 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28848085	Inhibitor 8146
Target ID: STAT3 signaling pathway Sources: https://www.ncbi.nlm.nih.gov/pubmed/27849557	Inhibitor 8146
autophagy 17 Target ID: GO:0006914 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27236003 \| https://www.ncbi.nlm.nih.gov/pubmed/27774504	Activator 1404

Conditions

Condition	Modality	Highest Phase	Product
Non-alcoholic fatty liver disease 29 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28932090 http://adisinsight.springer.com/drugs/800042917	Primary	Phase II 1133	Unknown Approved Use Unknown
Alzheimer’s disease 266 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28848085 https://www.ncbi.nlm.nih.gov/pubmed/28817221	Primary	Preclinical	Unknown Approved Use Unknown
Lung cancer 67 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27849557	Primary	Preclinical	Unknown Approved Use Unknown
Glioma 20 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27236003 https://www.ncbi.nlm.nih.gov/pubmed/27774504	Primary	Preclinical	Unknown Approved Use Unknown

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1532 inducer 753	inducer 372 inhibitor 1695	inhibitor 1789	inhibitor 1570

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1463 CYP2C8 869 UGT1A1 200 UGT1A9 115 CYP2A6 670 CYP2B6 770 CYP2C19 1410 UGT1A4 76 UGT2B7 145 UGT1A8 36 BCRP 678 SULT1E1 3 P-gp 1401 SULT1A1 4 UGT1A10 32 SULT1A2 1	SULT1A1 29 UGT1A10 289 SULT1A2 1 UGT1A1 417 UGT2B4 248 UGT1A3 421 UGT1A6 306 SULT1C4 3 SULT1B1 5 UGT2B7 387 UGT1A8 282 SULT1E1 17 UGT1A9 378 SULT2A1 24 UGT2B15 202 UGT1A4 345 SULT1A3 26 SULT1C2 1 UGT2B17 212 UGT1A7 235	CYP2C19 283 UGT1A1 66 CYP2B6 521 CYP2C8 163 CYP1A2 671 UGT1A4 8 UGT1A9 9 UGT2B7 14 SULT2A1 4

Drug as perpetrator

Target	Modality	Activity
CYP2B6 946	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/24005963/	moderate [IC50 13.8 uM]
CYP2D6 1826	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/24005963/	moderate [IC50 14 uM]
SULT1A1 8	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/	moderate [Ki 32.6 uM]
UGT1A4 79	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/24005963/	no [IC50 158.1 uM]
CYP3A4 1857	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/24005963/	no [IC50 97.3 uM]
BCRP 751	inhibitor 3185 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1325#sid=24823977	no
CYP1A2 1620	inducer 1515 Sources: https://pubmed.ncbi.nlm.nih.gov/25395831/	no
CYP2A6 702	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/24005963/	no
CYP2C19 1484	inducer 1515 Sources: https://pubmed.ncbi.nlm.nih.gov/25395831/	no
CYP2C8 923	inducer 1515 Sources: https://pubmed.ncbi.nlm.nih.gov/25395831/	no
CYP2C9 1747	inducer 1515 Sources: https://pubmed.ncbi.nlm.nih.gov/25395831/	no
CYP3A4 1857	inducer 1515 Sources: https://pubmed.ncbi.nlm.nih.gov/25395831/	no
SULT2A1 8	inducer 1515 Sources: https://pubmed.ncbi.nlm.nih.gov/25395831/	no
UGT1A1 249	inducer 1515 Sources: https://pubmed.ncbi.nlm.nih.gov/25395831/	no
UGT1A4 79	inducer 1515 Sources: https://pubmed.ncbi.nlm.nih.gov/25395831/	no
UGT1A9 120	inducer 1515 Sources: https://pubmed.ncbi.nlm.nih.gov/25395831/	no
UGT2B7 156	inducer 1515 Sources: https://pubmed.ncbi.nlm.nih.gov/25395831/	no
UGT1A10 41	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/	unlikely [Ki 1392 uM]
UGT1A8 48	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/	unlikely [Ki 1709 uM]
SULT1E1 3	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/	unlikely [Ki 262 uM]
UGT2B7 156	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/24005963/	weak [IC50 36.4 uM]
UGT1A1 249	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/24005963/	weak [IC50 50.5 uM]
SULT1A2 1	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/	weak [Ki 79.8 uM]
CYP2B6 946	inducer 1515 Sources: https://pubmed.ncbi.nlm.nih.gov/25395831/	weak
UGT1A9 120	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/24005963/	yes [IC50 0.96 uM]
CYP1A2 1620	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/24005963/	yes [IC50 2.1 uM]
CYP2C19 1484	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/24005963/	yes [IC50 2.2 uM]
CYP2C9 1747	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/24005963/	yes [IC50 4.1 uM]
CYP2C8 923	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/24005963/	yes [IC50 8.9 uM]
P-gp 1588	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/26454249/	yes
P-gp 1588	supressor 149 Sources: https://pubmed.ncbi.nlm.nih.gov/23060571/	yes

Drug as victim

Target	Modality	Activity
SULT1B1 5	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	likely [Km 0.41 uM]
SULT1C4 3	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/26983827/	likely
UGT1A6 306	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	likely
UGT1A9 378	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	likely
UGT2B15 202	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/26983827/	likely
UGT1A10 289	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	major [Km 1.32 uM]
UGT1A3 421	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	major [Km 3.67 uM]
SULT1E1 17	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	minor [Km 0.85 uM]
SULT1A3 26	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/	minor [Km 1.07 uM]
UGT2B17 212	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	minor
UGT2B7 387	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	minor
SULT1C2 1	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/26983827/	no
SULT2A1 24	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	no
UGT1A4 345	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	no
UGT2B4 248	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	no
UGT1A8 282	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	yes [Km 0.84 uM]
UGT1A1 417	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	yes [Km 1.82 uM]
SULT1A1 29	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	yes [Km 48 uM]
SULT1A2 1	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	yes [Km 92.3 uM]
UGT1A7 235	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/26983827/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1603	inhibitor 1584 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/720551#sid=49681541

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P003A2V	https://www.1pchem.com/search?query=1P003A2V
A2B Chem	AB52231	http://a2bchem.com/prod/AB52231
AA Blocks	AA0039JF	http://aablocks.com/goods/Goods/detail?id=AA0039JF
AK Scientific	J10347	https://aksci.com/item_detail.php?cat=J10347
AK Scientific	O900	https://aksci.com/item_detail.php?cat=O900
Ambeed	A146214	http://www.ambeed.com/search/Search.html?keyword=A146214
ApexBio Technology	N1672	https://www.apexbt.com/catalogsearch/result/?q=N1672
AstaTech	44247	http://astatechinc.com/CPSResult.php?CRNO=44247
BOC Sciences	35354-74-6	http://www.bocsci.com/description.asp?cas=35354-74-6
BioSynth	Q-100425	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/Q-100425
Biopurify Phytochemicals	BP0736	https://www.phytopurify.com/search.do?a=s&searchtype=3&psize=10&q=BP0736&searchhtmp=simplesearch&t=1
Cayman Chemical	14597	http://www.caymanchem.com/app/template/Product.vm/catalog/14597
Chem Scene	CS-1696	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-1696
Chem4Pharma	C4PN24	https://www.chem4pharma.com/product-page/C4PN24
ChemShuttle	141534	https://www.chemshuttle.com/catalogsearch/result/?q=141534
Combi-Blocks	QB-3220	http://www.combi-blocks.com/cgi-bin/find.cgi?QB-3220
Fluorochem	221573	http://www.fluorochem.co.uk/Products/Product?code=221573
Hairui	HOJB001	http://www.hairuichem.com/en/product/search.do?q=HOJB001
KeyOrganics	AS-15333	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-15333
Lab Network	LN00222478	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00222478
Lab Seeker	SC-17371	http://www.labseeker.com/search.php?keywords=SC-17371&category=0
LabSeeker	SC-17371	http://www.labseeker.com/search.php?keywords=SC-17371&category=0
MedChem Express	HY-N0003	https://www.medchemexpress.com/search.html?q=HY-N0003&ft=&fa=&fp=
MolPort	MolPort-002-507-432	https://www.molport.com/shop/molecule-link/MolPort-002-507-432
Molnova	M14205	https://www.molnova.com/en/serch-list.html?keywords=M14205
MuseChem	I003289	https://www.musechem.com/product/I003289.html
PI Chemicals	PI-28431	http://www.pipharm.com/catalog_products/PI-28431.html
Ryan Scientific	Magnolol	https://ryansci.com/products?q=Magnolol&list_q=&search_type=exact
Selleck Chemicals	S2310	http://www.selleckchem.com/search.html?searchDTO.searchParam=S2310
ShangHai Biochempartner	BCP28282	http://www.biochempartner.com/search_BCP28282
TargetMol	BBP02794	https://www.targetmol.com/search?keyword=BBP02794
TargetMol	T3001	https://www.targetmol.com/search?keyword=T3001
Tetrahedron	TS08538	http://www.thsci.com/search.do?q=TS08538
Tocris	4590	https://www.tocris.com/search.php?Type=QuickSearch&Value=4590
Toronto Research Chemicals	E950000	https://www.trc-canada.com/product-detail/?CatNum=E950000
Toronto Research Chemicals	H669560	https://www.trc-canada.com/product-detail/?CatNum=H669560
Vesino Industrial Co Ltd	VZ32385	http://www.vsnchem.com/search.do?a=s&psize=20&q=VZ32385
Vitas-M Laboratory	BBL027819	http://www.vitasmlab.biz/search/BBL027819
Vitas-M Laboratory	STK801954	http://www.vitasmlab.biz/search/STK801954
W&J PharmaChem	50C114705	http://wjpharmachem.com/new/searcht.php?keyword=50C114705
eMolecules	539203	https://orderbb.emolecules.com/search/#?query=539203
eNovation Chemicals	D401651	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D401651&searchbtn.x=0&searchbtn.y=0
mcule	MCULE-5001549020	https://mcule.com/MCULE-5001549020/

PubMed

Title	Date	PubMed
The anti-inflammatory effect of honokiol on neutrophils: mechanisms in the inhibition of reactive oxygen species production.	2003 Aug 15	12954355
The mechanism of honokiol-induced and magnolol-induced inhibition on muscle contraction and Ca2+ mobilization in rat uterus.	2003 Oct	14504686
Effects of Magnolol and Honokiol on the activities of streptococcal glucosyltransferases both in solution and adsorbed on an experimental pellicle.	2004	15482438
Inhibition of MAO A and B by some plant-derived alkaloids, phenols and anthraquinones.	2004 Apr	15120460
In vitro antibacterial and anti-inflammatory effects of honokiol and magnolol against Propionibacterium sp.	2004 Aug 2	15288590
Honokiol: a potent chemotherapy candidate for human colorectal carcinoma.	2004 Dec 1	15526365
[Pharmacokinetics of honokiol in rats].	2004 Feb	14970886
Antimicrobial and cytotoxic activities of neolignans from Magnolia officinalis.	2004 Mar	17191867
Anti-inflammatory effects of magnolol and honokiol are mediated through inhibition of the downstream pathway of MEKK-1 in NF-kappaB activation signaling.	2005 Apr	15856410
Anxiolytic agent, dihydrohonokiol-B, recovers amyloid beta protein-induced neurotoxicity in cultured rat hippocampal neurons.	2005 Aug 12-19	15899548
Novel curcumin- and emodin-related compounds identified by in silico 2D/3D conformer screening induce apoptosis in tumor cells.	2005 Aug 5	16083495
[Studies on HPLC chromatogram of phenolic constituents of Cortex Magnoliae Officinalis].	2005 Jul	16161419
Effects of magnolol and honokiol derived from traditional Chinese herbal remedies on gastrointestinal movement.	2005 Jul 28	16038044
Honokiol-induced neurite outgrowth promotion depends on activation of extracellular signal-regulated kinases (ERK1/2).	2005 Jun 1	15922325
Anti-arrhythmic effects of herbal medicine.	2005 Mar-Apr	16013349
Prokinetic effect of a Kampo medicine, Hange-koboku-to (Banxia-houpo-tang), on patients with functional dyspepsia.	2005 Nov	16323291
Honokiol protects against carbon tetrachloride induced liver damage in the rat.	2005 Nov	16317648
Honokiol inhibits TNF-alpha-stimulated NF-kappaB activation and NF-kappaB-regulated gene expression through suppression of IKK activation.	2005 Nov 15	16181613
Honokiol inhibits arterial thrombosis through endothelial cell protection and stimulation of prostacyclin.	2005 Sep	16115372
[Investigate into of effective constituent transference of herba Ephedrae and cortex Magnoliae officinalis in preparation course of Shujin Kechuan capsule].	2006 Dec	17348186
Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 1.	2006 Feb	17576437
Honokiol reduces oxidative stress, c-jun-NH2-terminal kinase phosphorylation and protects against glycochenodeoxycholic acid-induced apoptosis in primary cultured rat hepatocytes.	2006 Jun	16732532
Facile purification of honokiol and its antiviral and cytotoxic properties.	2006 Jun 1	16722664
Determination of honokiol and magnolol in cortex Magnoliae Officinalis by capillary electrophoresis with electrochemical detection.	2006 Jun 16	16704915
Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol.	2006 Nov 18	16406853
Simultaneous determination of honokiol and magnolol in Magnolia officinalis by liquid chromatography with tandem mass spectrometric detection.	2006 Oct	16583454
Honokiol causes the p21WAF1-mediated G(1)-phase arrest of the cell cycle through inducing p38 mitogen activated protein kinase in vascular smooth muscle cells.	2006 Oct 2	16962592
Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway.	2006 Sep	16966432
Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells.	2007 Apr 1	17326044
Honokiol, a neuroprotectant against mouse cerebral ischaemia, mediated by preserving Na+, K+-ATPase activity and mitochondrial functions.	2007 Aug	17651312
Synthesis, cytotoxicity, and antiviral activities of new neolignans related to honokiol and magnolol.	2007 Aug 15	17587572
Evaluation of the in vitro and in vivo genotoxicity of magnolia bark extract.	2007 Dec	17692444
Rapid purification and scale-up of honokiol and magnolol using high-capacity high-speed counter-current chromatography.	2007 Feb 23	17222860
Honokiol, a natural plant product, inhibits inflammatory signals and alleviates inflammatory arthritis.	2007 Jul 15	17617564
[Effects of the active compounds of M. officinalis on cariogenic bacteria].	2007 Jun	17593830
Magnolol and honokiol: inhibitors against mouse passive cutaneous anaphylaxis reaction and scratching behaviors.	2007 Nov	17978501
Protective action of honokiol, administered orally, against oxidative stress in brain of mice challenged with NMDA.	2007 Oct	17470388
Agmatine protects retinal ganglion cells from hypoxia-induced apoptosis in transformed rat retinal ganglion cell line.	2007 Oct 2	17908330
Effects of honokiol and magnolol on acute and inflammatory pain models in mice.	2007 Sep 8	17826802
Antidepressant-like effects of the mixture of honokiol and magnolol from the barks of Magnolia officinalis in stressed rodents.	2008 Apr 1	18093712
Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction.	2008 Feb 15	18281560
Anti-inflammatory effect of honokiol is mediated by PI3K/Akt pathway suppression.	2008 Jan	18158873
Preparation and characterization of honokiol nanoparticles.	2008 Jul	18197366
Rapid simultaneous quantification of five active constituents in rat plasma by high-performance liquid chromatography/tandem mass spectrometry after oral administration of Da-Cheng-Qi decoction.	2008 Jul 15	18358661
Enhancement of therapeutic effectiveness by combining liposomal honokiol with cisplatin in ovarian carcinoma.	2008 Jul-Aug	17892458
Enhanced effects of xanthohumol plus honokiol on apoptosis in 3T3-L1 adipocytes.	2008 Jun	18369342
Differential proteomic analysis of HeLa cells treated with Honokiol using a quantitative proteomic strategy.	2008 Jun	18157584
Chlorogenic acid and its metabolite m-coumaric acid evoke neurite outgrowth in hippocampal neuronal cells.	2008 Mar	18323641
Growth inhibitory effects of obovatol through induction of apoptotic cell death in prostate and colon cancer by blocking of NF-kappaB.	2008 Mar 17	18241858
Liposomal honokiol, a promising agent for treatment of cisplatin-resistant human ovarian cancer.	2008 Sep	18350317

Patents

Sample Use Guides

In Vivo Use Guide

High dose 400 mg and low dose 133.4 mg daily for 12 weeks

Route of Administration: Oral

In Vitro Use Guide

Honokiol inhibited the proliferation of both glioblastoma multiforme (GBM8401) parental cells and cancer stem-like side population (SP) cells in a dose-dependent manner, the IC50 were 5.3 and 11 uM, respectively. The proportions of cancer stem-like side population (SP) in GBM8401 cells were diminished by Honokiol from 1.5 % down to 0.3 % and 0.2 % at doses of 2.5 uM and 5 uM, respectively.

Substance Class	Chemical Created by `admin` on `Sat Dec 17 13:05:36 UTC 2022` Edited by `admin` on `Sat Dec 17 13:05:36 UTC 2022`
Record UNII	11513CCO0N
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

HONOKIOL

Official Name

English

HONOKIOL [MI]

Common Name

English

(1,1'-BIPHENYL)-2,4'-DIOL, 3',5-DI-2-PROPEN-1-YL-

Systematic Name

English

3',5-DIALLYL-2,4'-BIPHENYLDIOL

Systematic Name

English

NSC-293100

Code

English

PURINOL

Systematic Name

English

FMLT BSASM H

Brand Name

English

HONOKIOL [INCI]

Common Name

English

(1,1'-BIPHENYL)-2,4'-DIOL, 3',5-DI-2-PROPENYL-

Systematic Name

English

Honokiol [WHO-DD]

Common Name

English

Classification Tree Code System Code

DSLD

2680 (Number of products:8)